← European Medicine Shortage Tracker · all medicines
Epirubicin hydrochlorid currently has availability issues reported in 2 European registers: Austria, Greece.
Shortage ATC L01DB03 · also listed as: EPIRUBICIN HYDROCHLORID · EPIRUBICIN · data refreshed 7 August 2026
As of 7 August 2026, 2 of the 10 tracked registers list current availability issues for Epirubicin hydrochlorid, covering 4 affected product presentations. The longest-running open report was filed in Austria on 2021-11-09 and has now been open for about 57 months. Where agencies state a cause, delivery delays lead with 1 of the 1 stated-cause reports. The furthest expected-resolution date currently on file is 2026-10-30; the earliest is 2026-10-30. Notably, 1 report has already passed the expected-resolution date without closing — prognoses for this medicine should be read as estimates, not commitments. Registers in Greece indicate that alternatives or equivalents are available — a pharmacist or doctor can advise on switching. In the WHO ATC classification, Epirubicin hydrochlorid is coded L01DB03 — a medicine acting on antineoplastic and immunomodulating agents — so clinically related products appear under “Related medicines” below.
| Where | Status & products | Since | Expected end | Reason / alternatives | Source |
|---|---|---|---|---|---|
| 🇦🇹 Austria | Shortage Farmorubicin 200 mg Stechampulle + 1 more productsFarmorubicin 50 mg Stechampulle | 2021-11-09 | — | — | register ↗ |
| 🇬🇷 Greece | Limited availability BTX1VIAL+1AMPX5ML SOLV + 1 more productsFARMORUBICIN PD.INJ.SOL 50MG/VIAL BTx1VIAL | 2025-01-02 | 2026-10-30 | PFIZER ΕΛΛΑΣ Α.Ε. Καθυστέρηση παράδοσης περιεκτικότητας Alternatives: ΣΕ PERFORATED BLISTER (PVC/PE/PVDC//ALU) (UNIT Προβλήματα στην παραγωγική Εναλλακτικά άλλα | register ↗ |
Every individual register entry for Epirubicin hydrochlorid in the tracked sources, newest first — including resolved and discontinued reports.
| Reg. | Product | Status | Reported | Expected end | Stated reason |
|---|---|---|---|---|---|
| 🇬🇷 GR | FARMORUBICIN PD.INJ.SOL 50MG/VIAL BTx1VIAL | Limited availability | 2026-06-01 | 2026-07-31 | PFIZER ΕΛΛΑΣ Α.Ε. Αυξημένη ζήτηση Εναλλακτικά άλλα σκευάσματ |
| 🇬🇷 GR | BTX1VIAL+1AMPX5ML SOLV | Limited availability | 2025-01-02 | 2026-10-30 | PFIZER ΕΛΛΑΣ Α.Ε. Καθυστέρηση παράδοσης περιεκτικότητας |
| 🇦🇹 AT | Farmorubicin 50 mg Stechampulle | Shortage | 2022-02-07 | — | |
| 🇦🇹 AT | Farmorubicin 200 mg Stechampulle | Shortage | 2021-11-09 | — |
Yes. As of 7 August 2026, availability issues are reported in: Austria, Greece. Availability is national — a shortage in one country does not mean it is short everywhere.
Agency prognoses on file range from 2026-10-30 to 2026-10-30. These are manufacturer-reported estimates and frequently move; check the linked register entry for the latest date.
1 of the active register entries indicate alternatives or equivalents (same active substance or an alternative treatment). Do not switch on your own — a pharmacist or prescriber can confirm the right substitute in your country.
Directly from the official medicines-agency registers that list Epirubicin hydrochlorid: BASG (Austria), EOF limited-availability list (Greece). Every row on this page links to the underlying official record, and the dataset is refreshed from the primary sources every morning. Cross-language matching groups the same active substance across registers, so national spellings all resolve to this page.
Pharmacies, patient sites and newsrooms are welcome to embed the live status of Epirubicin hydrochlorid — free, with attribution. Copy this snippet:
<iframe src="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/epirubicin-hydrochlorid/embed.html" width="100%" height="150" loading="lazy" style="border:1px solid #e1e0d9;border-radius:12px" title="Epirubicin hydrochlorid availability in Europe"></iframe> <p style="font-size:12px">Source: <a href="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/epirubicin-hydrochlorid/">Epirubicin hydrochlorid shortage status — European Medicine Shortage Tracker</a> by MobiDoctor</p>